Meso Numismatics, Inc. Provides Earnings Guidance for the Fiscal Year 2024
January 31, 2024 at 05:54 pm IST
Share
Meso Numismatics, Inc. provided earnings guidance for the fiscal year 2024. The company expects to reach $5 million in revenues with approximately $1 million in operating profits (defined as gross profit less total operating expenses) for its fiscal year 2024. Although overall sales are expected to increase, the significant sales increase is expected to come from the patient procedure category as the Company?s Cancun based clinic starts to increase the total number of monthly patient procedures.
Meso Numismatics, Inc. is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary, Global Stem Cell Group Inc. It distributes stem cells and other regenerative based cell lines and equipment internationally and specializes in education and training physicians in regenerative medicine. It works with doctors and staff to provide products, solutions, equipment, services, and training to help them in the application of stem cell therapies. It is focused on the manufacturing and commercialization of viable cell therapy and immune support-related products. Its professional trademarked association, The International Society for Stem Cell Application (ISCCA), is a global network of medical professionals. Its flagship operation in Istanbul employs targeted combinations of exosomes, allogeneic human mesenchymal cells, and autologous bone marrow and adipose-derived stem cells to treat an array of diseases and debilitating medical conditions.
MESO NUMISMATICS, INC. 
